New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Informacje na temat projektu

PROTOCOL

Identyfikator umowy o grant: 673280

DOI

10.3030/673280

Projekt został zamknięty

Data podpisania przez KE 23 Kwietnia 2015

Data rozpoczęcia 1 Maja 2015

Data zakończenia 31 Października 2015

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

CIDQO 2012 SL
Spain

Periodic Reporting for period 1 - PROTOCOL (New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets)

Okres sprawozdawczy: 2015-05-01 do 2015-10-31

Podsumowanie kontekstu i ogólnych celów projektu

The PROTOCOL project (new PROcessing Technology fOr COListmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets) aimed through SME Instrument Phase 1 to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form. The specific objectives that were defined, and have been covered in the frame of the 1st Stage of SME Instrument are:
- To develop a business and exploitation plan.
- To undertake a commercial feasibility assessment.
- To widely disseminate project outcomes.
- To define the best practices for IPR management.
- To analyze in detail the regulatory standards to be met.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

The general goal of the current project is to fulfill the need of decreasing the current CMS market price and to undertake an innovation project to solve this limitation, through a new process to obtain CMS. In this sense, CIDQO has concluded that carrying the innovation project and launching CMS on the company’s specifications can be a successful business.

This period of time has been useful for specifying relevant elements of the business model and the tasks regarding to develop the exploitation model, undertaking the commercial feasibility assessment comprising logistics and marketing plan, disseminating the project outcomes, define the best practices for IPR management and analysing in detail the regulatory standards in order to ensure the success for commercial exploitation of the PROTOCOL’s results.

Summarizing:
• Launching CIDOQ’s cost-effective CMS through the new processing technology is a project with high margin
• A full market study has been undertaken.
• An IP study has been carried out.
• The project outcomes have been widely disseminated.
• SME Instrument Phases II and III will further develop the innovation.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

The expected growth of the company after the current SME Instrument Phase 1 and the subsequent Phase 2 will be very important. CIDQO should increase its net incomes and hence it foresees the creation of several new employments.

COListmethate sodium